It's gold if the drug/med is fully developed, has undisputed med data success and is approved by the FDA. Getting a patent is not a home run by itself. Btw, not very impressed with the 3 cent jump on the news today..if it holds the 3 cents.
I would also add here, like I did on another post, it would profit RNN believers to do a case study of AMRN. A company that has a very strong patent portfolio, an FDA approved medication that is now on the market, with many catalysts on the horizon this year. AMRN is on a much higher level than RNN as a bio-pharmaceutical stock, nevertheless the road to success is very complicated with risk.